Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
Myriad Genetics (NASDAQ: MYGN) has entered into a strategic collaboration with PATHOMIQ to exclusively license PATHOMIQ_PRAD, an AI technology platform for prostate cancer, in the United States. The partnership enhances Myriad's Oncology Solutions by combining molecular and AI-powered testing capabilities to inform treatment decisions for prostate cancer patients.
PATHOMIQ_PRAD's AI model delivers results within 1-2 days of receiving digital images and has demonstrated high prediction accuracy in both Caucasian and African American patient cohorts. The platform complements Myriad's existing Prolaris® Prostate Cancer Prognostic Test and can predict disease recurrence after initial therapy.
The collaboration aims to accelerate achieving Simon level 1 evidence for both tests. While currently specific for post-surgical prostate cancer patients, the foundational model has potential applications across all solid tumor cancers diagnosed through H&E staining biopsies. Myriad plans to launch its first AI-driven prostate cancer clinical test later in 2025.
Myriad Genetics (NASDAQ: MYGN) ha avviato una collaborazione strategica con PATHOMIQ per concedere in licenza esclusiva PATHOMIQ_PRAD, una piattaforma tecnologica AI per il cancro alla prostata, negli Stati Uniti. Questa partnership potenzia le soluzioni oncologiche di Myriad combinando capacità di test molecolari e basati su AI per informare le decisioni terapeutiche per i pazienti con cancro alla prostata.
Il modello AI di PATHOMIQ_PRAD fornisce risultati entro 1-2 giorni dal ricevimento delle immagini digitali e ha dimostrato un'alta precisione predittiva sia nei gruppi di pazienti caucasici che afroamericani. La piattaforma completa il test prognostico per il cancro alla prostata Prolaris® già esistente di Myriad e può prevedere la recidiva della malattia dopo la terapia iniziale.
La collaborazione mira ad accelerare il raggiungimento delle prove di livello 1 di Simon per entrambi i test. Sebbene attualmente sia specifica per i pazienti con cancro alla prostata post-chirurgico, il modello di base ha potenziali applicazioni in tutti i tumori solidi diagnosticati tramite biopsie con colorazione H&E. Myriad prevede di lanciare il suo primo test clinico per il cancro alla prostata guidato dall'AI entro la fine del 2025.
Myriad Genetics (NASDAQ: MYGN) ha entrado en una colaboración estratégica con PATHOMIQ para licenciar exclusivamente PATHOMIQ_PRAD, una plataforma de tecnología de IA para el cáncer de próstata, en los Estados Unidos. Esta asociación mejora las Soluciones Oncológicas de Myriad al combinar capacidades de pruebas moleculares y basadas en IA para informar las decisiones de tratamiento para los pacientes con cáncer de próstata.
El modelo de IA de PATHOMIQ_PRAD entrega resultados en 1-2 días tras recibir imágenes digitales y ha demostrado una alta precisión predictiva tanto en cohortes de pacientes caucásicos como afroamericanos. La plataforma complementa el Test Pronóstico de Cáncer de Próstata Prolaris® existente de Myriad y puede predecir la recurrencia de la enfermedad después de la terapia inicial.
La colaboración tiene como objetivo acelerar la obtención de evidencia de nivel 1 de Simon para ambas pruebas. Aunque actualmente es específica para pacientes con cáncer de próstata postquirúrgico, el modelo fundamental tiene aplicaciones potenciales en todos los cánceres de tumores sólidos diagnosticados a través de biopsias con tinción H&E. Myriad planea lanzar su primera prueba clínica para el cáncer de próstata impulsada por IA a finales de 2025.
Myriad Genetics (NASDAQ: MYGN)는 PATHOMIQ와 협력하여 미국에서 전립선암을 위한 AI 기술 플랫폼인 PATHOMIQ_PRAD를 독점적으로 라이센스하는 전략적 협력 관계를 맺었습니다. 이 파트너십은 전립선암 환자의 치료 결정을 알리기 위해 분자 및 AI 기반 테스트 기능을 결합하여 Myriad의 종양학 솔루션을 강화합니다.
PATHOMIQ_PRAD의 AI 모델은 디지털 이미지를 받은 후 1-2일 이내에 결과를 제공하며, 백인 및 아프리카계 미국인 환자 집단 모두에서 높은 예측 정확도를 입증했습니다. 이 플랫폼은 Myriad의 기존 Prolaris® 전립선암 예후 테스트를 보완하며 초기 치료 후 질병 재발을 예측할 수 있습니다.
협력의 목표는 두 테스트에 대한 Simon 수준 1 증거를 달성하는 속도를 높이는 것입니다. 현재는 수술 후 전립선암 환자에게 특정하지만, 기본 모델은 H&E 염색 생검을 통해 진단된 모든 고형 종양 암에 대한 잠재적 응용 가능성을 가지고 있습니다. Myriad는 2025년 말에 첫 번째 AI 기반 전립선암 임상 테스트를 출시할 계획입니다.
Myriad Genetics (NASDAQ: MYGN) a conclu une collaboration stratégique avec PATHOMIQ pour accorder une licence exclusive à PATHOMIQ_PRAD, une plateforme technologique d'IA pour le cancer de la prostate, aux États-Unis. Ce partenariat renforce les solutions oncologiques de Myriad en combinant des capacités de test moléculaire et d'IA pour informer les décisions de traitement des patients atteints de cancer de la prostate.
Le modèle d'IA de PATHOMIQ_PRAD fournit des résultats dans les 1 à 2 jours suivant la réception des images numériques et a montré une grande précision prédictive tant chez les patients caucasiens qu'afro-américains. La plateforme complète le test pronostique du cancer de la prostate Prolaris® déjà existant de Myriad et peut prédire la récidive de la maladie après un traitement initial.
La collaboration vise à accélérer l'obtention de preuves de niveau 1 de Simon pour les deux tests. Bien qu'elle soit actuellement spécifique aux patients atteints de cancer de la prostate post-chirurgical, le modèle fondamental a des applications potentielles dans tous les cancers des tumeurs solides diagnostiqués par biopsies colorées à l'H&E. Myriad prévoit de lancer son premier test clinique pour le cancer de la prostate piloté par l'IA d'ici fin 2025.
Myriad Genetics (NASDAQ: MYGN) hat eine strategische Zusammenarbeit mit PATHOMIQ eingegangen, um PATHOMIQ_PRAD, eine KI-Technologieplattform für Prostatakrebs, exklusiv in den Vereinigten Staaten zu lizenzieren. Die Partnerschaft verbessert Myriads Onkologie-Lösungen, indem sie molekulare und KI-gestützte Testmöglichkeiten kombiniert, um Behandlungsentscheidungen für Prostatakrebspatienten zu informieren.
Das KI-Modell von PATHOMIQ_PRAD liefert Ergebnisse innerhalb von 1-2 Tagen nach Erhalt digitaler Bilder und hat eine hohe Vorhersagegenauigkeit sowohl in kaukasischen als auch in afroamerikanischen Patientenkohorten gezeigt. Die Plattform ergänzt den bestehenden Prolaris® Prostatakrebs-Prognosetest von Myriad und kann das Wiederauftreten der Krankheit nach der Ersttherapie vorhersagen.
Die Zusammenarbeit zielt darauf ab, den Nachweis der Simon-Stufe 1 für beide Tests zu beschleunigen. Während es derzeit spezifisch für postchirurgische Prostatakrebspatienten ist, hat das grundlegende Modell potenzielle Anwendungen in allen soliden Tumoren, die durch H&E-Färbe-Biopsien diagnostiziert werden. Myriad plant, Ende 2025 seinen ersten KI-gesteuerten klinischen Test für Prostatakrebs auf den Markt zu bringen.
- Exclusive licensing agreement for AI technology in the US market
- Quick turnaround time of 1-2 days for test results
- Demonstrated high prediction accuracy across different patient cohorts
- Potential for expansion into other solid tumor cancer applications
- Commercial launch of AI-driven test planned for 2025
- Technology currently to post-surgical prostate cancer applications
- Simon level 1 evidence not yet achieved for the tests
Insights
This strategic collaboration marks a pivotal expansion of Myriad Genetics' diagnostic capabilities in the $3.1 billion prostate cancer testing market. The integration of PATHOMIQ's AI platform represents a significant competitive advantage through three key differentiators:
- Rapid turnaround time of 1-2 days for results, compared to traditional molecular testing that typically takes 5-7 days
- Enhanced prediction accuracy that outperforms current markers, particularly validated across diverse patient populations
- Cost-efficient scalability potential across multiple solid tumor types beyond prostate cancer
The partnership strategically positions Myriad to capture additional market share by offering a comprehensive testing solution that spans the entire patient journey - from initial biopsy through post-treatment monitoring. The AI platform's ability to decode morphological structures creates a robust technological moat, while the exclusive licensing agreement provides market protection.
The planned commercial launch later this year suggests near-term revenue potential, with several growth catalysts:
- Accelerated timeline for achieving Simon level 1 evidence validation
- Expansion opportunities into other solid tumor applications
- Potential for improved reimbursement rates due to enhanced clinical utility
The integration of AI technology also aligns with broader industry trends toward precision medicine and could lead to improved operational efficiency through reduced costs and faster turnaround times. This positions Myriad favorably against competitors in the molecular diagnostics space while creating barriers to entry through proprietary AI algorithms and validated clinical data.
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology platform for prostate cancer, in the United States.
Machine learning and AI-enabled diagnostics are transforming the way clinicians approach cancer patient care. Adding PATHOMIQ_PRAD to Myriad’s Oncology Solutions allows Myriad to provide urologist and radiation oncologists with molecular and AI-powered testing solutions to inform decisions both before treatment at the time of biopsy for active surveillance and following surgery or radiation treatment. This complements Myriad’s existing offerings of combined germline and comprehensive tumor profiling as recommended by NCCN guidelines for prostate cancer care.
“Along with our Prolaris® Prostate Cancer Prognostic Test, we are pleased to leverage PATHOMIQ’s prognostic and predictive capabilities across different phases of the patient journey in prostate cancer,” said George Daneker, Jr., MD, President and Chief Clinical Officer, Oncology, Myriad Genetics. “Having both genetic and morphologic insights at the time of biopsy combined with the enhanced ability to predict disease recurrence after initial therapy can lead to more informed treatment decisions and enhance the potential for better patient outcomes. This partnership is the latest step in the strategic expansion of Myriad’s oncology portfolio. Our molecular science expertise, combined with the latest in machine learning and AI, will uniquely position Myriad to deliver higher-quality insights for patients and clinicians in the fight against cancer.”
PATHOMIQ’s AI-technology platform decodes hidden information from complex morphological structures across all landscapes of cancer pathology to quickly and efficiently deploy new use cases to predict patient outcome, treatment response, and genotype mutations. This image-based technology can deliver results in one to two days after receiving the digital images from the patient's sample.
“I am excited to have co-developed, with the PATHOMIQ team, the PATHOMIQ-PRAD AI model for prostate cancer treatment response prediction and identification of high-risk prostate cancer patients who will experience early metastasis post Radical Prostatectomy,” said Ashutosh K. Tewari, Chairman, Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mt Sinai. “The AI model has achieved high prediction accuracy and outperformed some of the currently used markers in both Caucasian and African American patient cohorts for a much-improved patient outcome.”
In addition to expanding Myriad’s prostate cancer testing portfolio to include post-surgical treatment testing solutions, the collaboration with PATHOMIQ is also envisioned to accelerate the timelines for meeting Simon level 1 evidence for both Prolaris and PATHOMIQ_PRAD. While the current PATHOMIQ_PRAD model is specific for use in patients with prostate cancer after surgery, the underlying foundational model provides opportunities for applications in virtually all solid tumor cancers that are diagnosed through a biopsy with H&E staining.
“Our collaboration with Myriad, a leader in cancer diagnostic tests, will help to advance precision medicine and improve prostate cancer disease outcomes,” said Rajat Roy, CEO and co-founder of PATHOMIQ. “Our AI-powered model has been successfully validated across multiple medical institutions and pharmaceutical partners. Combining Myriad’s extensive clinical expertise and broad customer reach with PATHOMIQ’s AI technology platform will allow more personalized treatment options for clinicians and their patients.”
Paul J. Diaz, President and CEO of Myriad, adds “PATHOMIQ’s technology platform, together with Myriad’s infrastructure and commercial capabilities allows for an accelerated pace of innovation to bring advanced diagnostic products to market that are clinically validated with faster turnaround times and at a lower cost.”
Myriad intends to commercially launch its first AI-driven prostate cancer clinical test later this year.
About PATHOMIQ
PATHOMIQ’s AI technology extracts hidden insights from complex cancer pathology to support faster and more accurate clinical decisions. By analyzing digital biopsy or surgical specimen images, it predicts patient outcomes and treatment response. This image-based approach can deliver results within one day of receiving the digital images from the patient's biopsy or surgical sample, helping clinicians make timely and informed treatment decisions. For more information, visit www.pathomiq.com.
About the PATHOMIQ AI Platform
PATHOMIQ’s unique AI platform is supported by extensive key opinion leader engagement and six completed or ongoing studies and also completed and ongoing clinical trial data qualified to support Simon level 1 development. Four issued and multiple pending patents, including specific uses cases in prostate and breast cancer, support the platform architecture.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s intent to commercially launch its first AI-driven prostate cancer clinical test later this year, the expectation that this new test would enable the company to offer both AI and molecular testing options for prostate cancer, eventually spanning all phases of the prostate cancer patient journey, the collaboration marks an innovative and strategic expansion of the company’s clinical oncology portfolio, and the belief that PATHOMIQ’s AI-powered imaging is a promising approach to defining more personalized outcome predictions and therapies. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
What is the significance of Myriad Genetics' partnership with PATHOMIQ for MYGN stock?
When will Myriad Genetics (MYGN) launch its first AI-driven prostate cancer test?
How does PATHOMIQ_PRAD complement Myriad's existing Prolaris test?
What is the turnaround time for PATHOMIQ_PRAD test results for MYGN customers?
What are the potential expansion opportunities for MYGN's PATHOMIQ partnership?
